Tilray Brands Reports Record Q2 Fiscal 2026 Revenue of $218 Million
Tilray Brands, Inc. (Nasdaq: TLRY; TSX: TLRY), a prominent player in the global cannabis and wellness industry, has announced impressive financial results for its second fiscal quarter closing on November 30, 2025. The company achieved a record net revenue of $218 million, showcasing robust growth across its diversified portfolio. This development emphasizes Tilray's capacity to adapt and thrive in competitive markets, ultimately aiming for sustainable profitability.
Key Financial Highlights
In comparison to the previous year, Tilray's financial performance illustrates notable improvements:
- Net revenue: Increased 3% to $217.5 million from $211.0 million
- Gross profit: Reported at $57.5 million, down slightly from $61.2 million
- Gross margin: Decreased to 26% compared to 29%
- Cannabis net revenue: Up 3% to $67.5 million, driven by a 36% rise in international cannabis sales
- Beverage net revenue: Declined to $50.1 million from $63.1 million
- Adjusted EBITDA: Recorded at $8.4 million, down from $9.0 million
These figures reflect both the challenges and successes within different sectors of Tilray's operations, particularly emphasizing strong growth in international cannabis sales.
Financial Management and Strategic Initiatives
Irwin D. Simon, Chairman and CEO of Tilray, expressed optimism regarding the company's financial health and strategic direction. “The quarter concluded with a strong balance sheet and ample liquidity, highlighting our prudent financial management,” Simon said. He emphasized that the company's model fosters scalable and adaptable operations, setting the stage for long-term value creation.
Tilray ended the quarter with approximately $292 million in cash and marketable securities, coupled with a robust net cash position of around $30 million. This strong financial foundation provides Tilray the flexibility necessary for investment in strategic growth initiatives.
Growing Opportunities in Medical Cannabis
Looking ahead, Tilray is poised to capitalize on anticipated U.S. federal cannabis rescheduling. Simon stated, “We believe federal rescheduling would mark an important advancement for medical cannabis in the United States.” This change is expected to enhance research, increase physician involvement, and improve patient access within the medical cannabis sector.
With a strategic focus on leveraging its existing infrastructure, Tilray is positioned to expand its medical operations significantly. The plan includes further research initiatives and new FDA trials, reinforcing Tilray's commitment to become a key player in the U.S. medical cannabis market.
Future Outlook
Tilray has reaffirmed its adjusted EBITDA guidance for fiscal 2026, anticipating a range between $62 million and $72 million. Investors and stakeholders can tune in to a live audio webcast today at 4:30 p.m. Eastern Time for further insights into these results and the company's strategic direction.
The webcast will be accessible through the Events & Presentations section of Tilray's Investor Relations website, with a replay available post-event.
About Tilray Brands
Tilray Brands, Inc. is a leading global lifestyle and consumer packaged goods company, facilitating experiences at the intersection of cannabis, beverage, wellness, and entertainment. The company’s diverse portfolio includes over 40 brands across more than 20 countries, showcasing comprehensive cannabis offerings, hemp-based foods, and craft beverages.
For more information, visit Tilray.com and follow @Tilray on social media platforms.